Akebia Therapeutics
AKBA
143 hedge funds and large institutions have $203M invested in Akebia Therapeutics in 2025 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 64 increasing their positions, 26 reducing their positions, and 4 closing their positions.
625% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 4
146% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 26
58% more capital invested
Capital invested by funds: $129M → $203M (+$74.3M)
18% more funds holding
Funds holding: 121 → 143 (+22)
5.46% more ownership
Funds ownership: 31.1% → 36.56% (+5.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
45% less call options, than puts
Call options by funds: $654K | Put options by funds: $1.19M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$10.2M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$5.97M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$5.1M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$5.07M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$4.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$251K |
| 2 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
-$201K |
| 3 |
Barclays
London,
United Kingdom
|
-$137K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$127K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$116K |
AKBA Hedge Fund Activity: Q1 2025 in Review
143 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2025, worth a combined $203M — up 58% from $129M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new AKBA positions and 4 closed out — a net gain of 25 holders — while 64 added to existing stakes and 26 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $10.2M. The largest seller was Qube Research & Technologies (QRT), cutting an estimated $251K.
- 143 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2025, up from 121 in Q4 2024.
- Funds reported $203M of Akebia Therapeutics stock for Q1 2025, up 58% quarter-over-quarter.
- 29 funds opened new Akebia Therapeutics positions in Q1 2025 and 4 closed out, a net change of +25 holders.
- The largest Akebia Therapeutics buyer in Q1 2025 was Great Point Partners, an estimated $10.2M added.
- The largest Akebia Therapeutics seller in Q1 2025 was Qube Research & Technologies (QRT), an estimated $251K sold.
Based on aggregated 13F filings for Q1 2025.